Posted by Michael Wonder on 15 Jan 2025
Acadia Pharmaceuticals submits marketing authorisation application to the EMA for trofinetide for the treatment of Rett syndrome
14 January 2025 - Filing marks company’s first marketing authorisation application in Europe.
Acadia Pharmaceuticals today announced that the company has submitted a marketing authorisation application to the EMA for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
